Glivec approved for GIST treatment

Published: 2009-03-12 06:57:00

Updated: 2009-03-12 06:57:00

The Korea Food and Drug Administration on March 4 approved the Novartis drug Glivec (imatinib mesylate) for the treatment of patients with Kit (CD 117) positive unresectable (inoperable) and/or metastatic malignant gastrointestinal stromal tumors (GISTs).

The effectiveness of Glivec in GIST is...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK